MedTrace Logo

Twice-per-weekSelinexor, 2 Days Melphalan

NCT06613035 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2024-09-25

No results posted yet for this study

Summary

Twice-per-week Selinexor, 2 days Melphalan plus BU2FLU3 compared with BU3FLU5 for elder high-risk acute myeloid leukemia undergoing allogenic hematopoietic cell transplantation: a multi-center randomized phase 3 trial

Conditions

Interventions

DRUG

Selinexor

Selinexor: 60 mg/day from days -9 to -5.

DRUG

Melphalan

Selinexor: 60 mg/day from days -9 to -5.

DRUG

Intravenous Busulfan

3.2 mg/kg on days

DRUG

Fludarabine

30 mg/m² on days

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613035 on ClinicalTrials.gov